Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter M Irving

Showing results (121-130 of 195) with videos related to

Pageof 20
Sort By:
Inflammatory Bowel Diseases|October 18, 2018
Validation and Investigation of the Operating Characteristics of the Ulcerative Colitis Endoscopic Index of SeverityDjuna C de Jong, Mark Löwenberg, Ioannis Koumoutsos, et al.
Gastroenterology & Hepatology|October 1, 2011
Current Controversies in Crohn's Disease: A Roundtable Discussion of the BRIDGe GroupMiles P Sparrow, Peter M Irving, Leonard Baidoo, et al.
Alimentary Pharmacology & Therapeutics|July 5, 2021
An observational study of switching infliximab biosimilar: no adverse impact on inflammatory bowel disease control or drug levels with first or second switchRaphael P Luber, Rhona O'Neill, Sukhpreet Singh, et al.
Cellular and Molecular Gastroenterology and Hepatology|June 6, 2022
Cyclin-dependent Kinase 9 as a Potential Target for Anti-TNF-resistant Inflammatory Bowel DiseaseOmer S Omer, Arnulf Hertweck, Luke B Roberts, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 26, 2024
Efficacy and Safety of Upadacitinib for Perianal Fistulizing Crohn's Disease: A Post Hoc Analysis of 3 Phase 3 TrialsJean-Frédéric Colombel, Ana P Lacerda, Peter M Irving, et al.
The New England Journal of Medicine|June 28, 2023
Mirikizumab as Induction and Maintenance Therapy for Ulcerative ColitisGeert D'Haens, Marla Dubinsky, Taku Kobayashi, et al.
Inflammatory Bowel Diseases|April 4, 2025
Assessment and Impact of Age on the Safety and Efficacy of Etrasimod in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From the ELEVATE UC Clinical ProgramGary R Lichtenstein, Jessica R Allegretti, Edward V Loftus, et al.
Inflammatory Bowel Diseases|August 22, 2015
Prevalence and Risk Factors for Functional Vitamin B12 Deficiency in Patients with Crohn's DiseaseMark G Ward, Viraj C Kariyawasam, Sathis B Mogan, et al.
Science (New York, N.Y.)|September 14, 2023
Conserved γδ T cell selection by BTNL proteins limits progression of human inflammatory bowel diseaseRobin J Dart, Iva Zlatareva, Pierre Vantourout, et al.
Journal of Crohn'S & Colitis|September 2, 2025
Faecal loss of vedolizumab is associated with UC severity, lower serum vedolizumab levels and rates of clinical response: Results from the FAVOUR studyMark A Samaan, Georgina Cunningham, Samuel Hsiang Lim, et al.
Pageof 20

Showing results (121-130 of 195) with videos related to

Sort By:
Pageof 20
Inflammatory Bowel Diseases|October 18, 2018
Validation and Investigation of the Operating Characteristics of the Ulcerative Colitis Endoscopic Index of SeverityDjuna C de Jong, Mark Löwenberg, Ioannis Koumoutsos, et al.
Gastroenterology & Hepatology|October 1, 2011
Current Controversies in Crohn's Disease: A Roundtable Discussion of the BRIDGe GroupMiles P Sparrow, Peter M Irving, Leonard Baidoo, et al.
Alimentary Pharmacology & Therapeutics|July 5, 2021
An observational study of switching infliximab biosimilar: no adverse impact on inflammatory bowel disease control or drug levels with first or second switchRaphael P Luber, Rhona O'Neill, Sukhpreet Singh, et al.
Cellular and Molecular Gastroenterology and Hepatology|June 6, 2022
Cyclin-dependent Kinase 9 as a Potential Target for Anti-TNF-resistant Inflammatory Bowel DiseaseOmer S Omer, Arnulf Hertweck, Luke B Roberts, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 26, 2024
Efficacy and Safety of Upadacitinib for Perianal Fistulizing Crohn's Disease: A Post Hoc Analysis of 3 Phase 3 TrialsJean-Frédéric Colombel, Ana P Lacerda, Peter M Irving, et al.
The New England Journal of Medicine|June 28, 2023
Mirikizumab as Induction and Maintenance Therapy for Ulcerative ColitisGeert D'Haens, Marla Dubinsky, Taku Kobayashi, et al.
Inflammatory Bowel Diseases|April 4, 2025
Assessment and Impact of Age on the Safety and Efficacy of Etrasimod in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From the ELEVATE UC Clinical ProgramGary R Lichtenstein, Jessica R Allegretti, Edward V Loftus, et al.
Inflammatory Bowel Diseases|August 22, 2015
Prevalence and Risk Factors for Functional Vitamin B12 Deficiency in Patients with Crohn's DiseaseMark G Ward, Viraj C Kariyawasam, Sathis B Mogan, et al.
Science (New York, N.Y.)|September 14, 2023
Conserved γδ T cell selection by BTNL proteins limits progression of human inflammatory bowel diseaseRobin J Dart, Iva Zlatareva, Pierre Vantourout, et al.
Journal of Crohn'S & Colitis|September 2, 2025
Faecal loss of vedolizumab is associated with UC severity, lower serum vedolizumab levels and rates of clinical response: Results from the FAVOUR studyMark A Samaan, Georgina Cunningham, Samuel Hsiang Lim, et al.
Pageof 20